Understanding Stiff Person Syndrome: A Rare Neurological Challenge

Stiff Person Syndrome (SPS), a rare autoimmune neurological disorder, affects the central nervous system by causing progressive muscle rigidity and painful spasms, primarily in the trunk and limbs. First described in 1956, SPS impacts approximately one to two people per million worldwide, with women comprising about 70 percent of cases. Onset typically occurs between ages 30 and 60, though pediatric variants exist. The hallmark symptoms include fluctuating muscle stiffness that worsens with stress or sudden movements, episodic spasms triggered by noise or touch, heightened sensitivity to stimuli, and lumbar hyperlordosis leading to falls and mobility loss. Over time, many patients require walking aids or wheelchairs, facing a lifetime of disability without disease-modifying treatments.

At its core, SPS stems from autoantibodies targeting glutamic acid decarboxylase 65 (GAD65), an enzyme essential for synthesizing gamma-aminobutyric acid (GABA), the brain's primary inhibitory neurotransmitter. In about 60-80 percent of cases, anti-GAD65 antibodies disrupt GABAergic inhibition, causing hyperexcitability in motor neurons. Other variants involve antibodies against glycine receptors (GlyR) or amphiphysin, expanding the spectrum. Associated conditions like diabetes type 1, pernicious anemia, or thyroiditis highlight its autoimmune roots. Diagnosis relies on clinical features, elevated antibody titers, electromyography showing continuous motor unit activity, and response to GABAergic drugs like diazepam or baclofen.

The Limitations of Existing SPS Management

Current SPS care focuses on symptom relief rather than addressing the underlying autoimmunity. Intravenous immunoglobulin (IVIg) or plasma exchange (PLEX) offers temporary respite by reducing antibody levels, while rituximab—a B-cell depleting monoclonal antibody—shows inconsistent benefits in small studies. Symptomatic therapies include muscle relaxants, anticonvulsants like gabapentin, pain modulators, and physical therapy to maintain flexibility. However, these interventions fail to halt progression; up to 65 percent of patients experience worsening mobility within five years, with chronic immunotherapy needs burdening quality of life and healthcare systems. The absence of FDA-approved therapies underscores an urgent unmet need, propelling academic researchers toward innovative immunotherapies.

CAR-T Cell Therapy Emerges from Cancer Research to Autoimmunity

Chimeric Antigen Receptor T-cell (CAR-T) therapy, pioneered in oncology over the past decade, reprograms a patient's T cells to target specific proteins. In autoimmune diseases like SPS, the strategy shifts to CD19, a marker on B cells—the source of pathogenic autoantibodies. The process unfolds in steps: T cells are harvested via leukapheresis, genetically engineered ex vivo to express a CAR construct recognizing CD19, expanded in culture, and reinfused after lymphodepleting chemotherapy clears competing immune cells. This achieves profound, transient B-cell aplasia, resetting aberrant immunity without broad immunosuppression. Universities like the University of Pennsylvania and National Cancer Institute laid foundational work adapting CAR-T for autoimmunity, with early compassionate uses in refractory lupus and multiple sclerosis paving the way for SPS applications.

The KYSA-8 Trial: University-Led Pivotal Study Details

KYSA-8 (NCT06588491), a Phase 2 open-label, single-arm multicenter trial sponsored by Kyverna Therapeutics, enrolled 26 adults with refractory SPS. Participants, median age 56, had stiffness index scores of at least 2 and failed prior immunomodulators like IVIg, PLEX, or rituximab. After low-dose cyclophosphamide and fludarabine lymphodepletion, they received a single infusion of mivocabtagene autoleucel (miv-cel) at 1x10^8 CAR T cells. Key sites included the University of Colorado Anschutz Medical Campus, Thomas Jefferson University, and Mayo Clinic, reflecting robust academic collaboration. Primary analysis at Week 16 (median follow-up 6.5 months) powered the registrational dataset presented at the American Academy of Neurology (AAN) 2026 meeting.

Groundbreaking Results: Restoring Mobility and Function

Miv-cel delivered transformative outcomes across endpoints. The primary measure, Timed 25-Foot Walk (T25FW), showed a median 46 percent improvement (p=0.0003), with 81 percent achieving at least 20 percent gain—surpassing minimal clinically important differences. Nearly one-third walked at healthy adult speeds, and 67 percent of the 12 baseline aid-dependent patients walked unaided. Secondary scales reflected broad gains: Modified Rankin Scale improved by -0.8 points, Hauser Ambulation Index by -1.6, Distribution of Stiffness Index by -1.5, and Heightened Sensitivity Scale by -3.2 (all p<0.0001). Exploratory metrics like the 6-Minute Walk Test exceeded fourfold the important change threshold. All 26 patients discontinued chronic immunotherapies, with GAD65 autoantibody titers plummeting. Responses endured, hinting at disease modification.

• Median T25FW baseline: 11.1 seconds; Week 16: 46 percent faster.
• Ambulatory aid reduction: From 46 percent dependent to minimal.
• Quality of life: SF-36 scores normalized toward healthy norms.

Academic Leadership Driving the Breakthrough

University researchers spearheaded KYSA-8 success. Amanda Piquet, MD, Director of Autoimmune Neurology at University of Colorado Anschutz Medical Campus and Céline Dion Foundation Endowed Chair, served as lead investigator. Her team, treating high-profile cases like singer Céline Dion, advances SPS through dedicated labs and trials. Co-investigators include Marinos Dalakas, MD, at Thomas Jefferson University, a neuromuscular pioneer, and experts at Mayo Clinic. CU Anschutz hosts the 2026 SPS Symposium (June 13-14), fostering global collaboration. These institutions provide natural history data, patient cohorts, and translational expertise, positioning higher education at the forefront of neuroimmunology innovation.

Safety and Manageability: Paving the Way for Broader Use

Miv-cel proved well-tolerated, supporting potential outpatient delivery. Cytokine release syndrome (CRS) occurred in 92 percent (all Grade 1-2), immune effector cell-associated neurotoxicity syndrome (ICANS) in 12 percent (Grade 1 only), and Grade 3/4 neutropenia in 62 percent—all resolved without sequelae. No treatment-related deaths or high-grade events marred the profile, contrasting oncology CAR-T risks. This differentiated safety, honed through academic refinements, addresses physician hesitancy in non-oncology settings.

Real Patient Transformations and Quality of Life Gains

Individual trajectories inspire: One patient slashed T25FW from 18.3 to 5.0 seconds (73 percent gain), resuming running. Another transitioned from walker dependency to independent ambulation, reclaiming daily activities. Reduced spasms alleviated chronic pain, anxiety diminished, and hypersensitivity waned, enabling social reintegration. For the estimated 6,000 U.S. SPS patients—90 percent on symptomatic care, 30-40 percent on off-label immunotherapy—these shifts promise independence restoration, echoing compassionate cases in Europe where walking distances surged from 50 meters to kilometers post-CAR-T.

Toward FDA Approval and Expanding Research Frontiers

Buoyed by KYSA-8, Kyverna plans Biologics License Application submission in H1 2026, potentially yielding the first SPS approval—and inaugural autoimmune CAR-T. Ongoing monitoring through Year 1 will affirm durability. Parallel trials in myasthenia gravis (KYSA-6) and lupus bolster the platform. Academic centers eye pediatric SPS, variant phenotypes, and combination therapies. Funding surges, with NIH and foundations like SPSRF amplifying university efforts. As detailed in Kyverna's AAN presentation, this heralds a neuroimmunology renaissance.

Implications for Higher Education and Future Careers

This breakthrough spotlights neuroimmunology as a burgeoning field, demanding interdisciplinary talent in immunology, neurology, gene editing, and trial design. Universities like CU Anschutz and Mayo train postdocs, fellows, and faculty via endowed chairs and symposia, fostering careers in translational research. Rising NIH grants for rare diseases attract PhDs to CAR-T optimization, biomarker discovery, and long-term registries. For aspiring researchers, SPS exemplifies how academic rigor translates to patient impact, urging enrollment in clinical research programs and collaborations with biotechs.

Global Outlook: Reshaping Autoimmune Treatment Paradigms

Beyond SPS, miv-cel's success validates CD19 CAR-T for B-cell driven autoimmunity, from multiple sclerosis to rheumatoid arthritis. Challenges persist—manufacturing scalability, access equity, relapse risks—but academic innovation addresses them via allogeneic CAR-T and precision biomarkers. With prevalence underestimations emerging (higher than 1/million), early screening and multidisciplinary care gain traction. This university-driven milestone not only restores mobility for SPS sufferers but ignites hope across immunology, proving targeted immune reset can reverse devastation once deemed irreversible.

Photo by Vitaly Gariev on Unsplash